Evidence map›Paper›PMID 17967299›Full record

ArticleInternational journal of radiation oncology, biology, physics2007

Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.

Sydney M Evans, Kevin L Du, Ara A Chalian, Rosemarie Mick, Paul J Zhang, Stephen M Hahn, Harry Quon, Robert Lustig, Gregory S Weinstein, Cameron J Koch

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids.Journal of experimental & clinical cancer research : CR · 2017
    Review
  7. Article
  8. Molecular mechanisms of hypoxia in cancer.Clinical and translational imaging · 2017
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014
    Article
  14. Article
  15. Hypoxia and fetal heart development.Current molecular medicine · 2010
    Review
  16. Article
  17. Review
  18. Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2010
    Review
  19. Article
  20. Molecular aspects of tumour hypoxia.Molecular oncology · 2008
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sydney M EvansDepartment of Radiation Oncology, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6072, USA. sydevans@mail.med.upen.edu
Kevin L Du
Ara A Chalian
Rosemarie Mick
Paul J Zhang
Stephen M Hahn
Harry Quon
Robert Lustig
Gregory S Weinstein
Cameron J Koch
University of Pennsylvania · US

Funding

SPECIALIZED CENTER OF RESEARCH IN HYPERBARIC OXYGEN THERP50AT000428 · NCCIH · UNIVERSITY OF PENNSYLVANIA · PI THOM, STEPHEN RAYMOND · 2000 to 2004
$7.9M
DOES HYPOXIA PREDICT RADIATION/SURGICAL TUMOR RESPONSE?R01CA075285 · NCI · UNIVERSITY OF PENNSYLVANIA · PI EVANS, SYDNEY M · 1997 to 2005
$2.0M
Imaging and Modifying Hypoxia in Head and Neck Squamous Cell TumorsR01CA129349 · NCI · UNIVERSITY OF PENNSYLVANIA · PI EVANS, SYDNEY M. · 2008 to 2013
$1.3M
TUMOR HETEROGENEITY CORRELATION TO RADIOSENSITIVITYR29CA062331 · NCI · UNIVERSITY OF PENNSYLVANIA · PI EVANS, SYDNEY M · 1995 to 1999
–
NCCIH NIH HHS 1 P50 AT00428-01NCI NIH HHS CA 75285NCI NIH HHS R01 CA075285NCI NIH HHS R01 CA129349NCI NIH HHS R29 CA062331
6 · The paper itself

Abstract

purposeEF5, a 2-nitroimidazole hypoxia marker, was used to study the presence, levels, and prognostic significance of hypoxia in primary head and neck squamous cell tumors. METHODS AND MATERIALS: Twenty-two patients with newly diagnosed squamous cell carcinoma of the oral cavity, oropharynx, or larynx with at least 2 years of clinical follow-up were included in this study. Quantitative analyses of EF5 immunofluorescence was carried out, and these data were compared with patient outcome.

resultsEF5 immunostaining showed substantial intra- and intertumoral hypoxic heterogeneity. The majority of cells in all tumors were well oxygenated. Three patterns of EF5 binding in cells were identified using criteria based on the cellular region that was stained (peripheral or central) and the relationship of binding to necrosis. We tested the association between EF5-binding levels with event-free and overall survival irrespective of the pattern of cellular binding or treatment regimen. Patients with tumors containing EF5-binding regions corresponding to severe hypoxia (< or =0.1% oxygen) had a shorter event-free survival time than patients with pO(2) values greater than 0.1% (p = 0.032). Nodal status was also predictive for outcome.

conclusionsThese data illustrate the potential utility of EF5 binding based on quantitative immunohistochemistry of tissue pO(2) and provide support for the development of noninvasive hypoxia positron emission tomographic studies with fluorine 18-labeled EF5.

Indexed as

Cell HypoxiaAgedCarcinoma, Squamous CellEtanidazoleFemaleFluorescent Antibody TechniqueFluorocarbonsHead and Neck NeoplasmsHumansHydrocarbons, FluorinatedIndicators and ReagentsLaryngeal NeoplasmsMaleMiddle AgedMouth NeoplasmsOropharyngeal Neoplasms2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamideEtanidazoleFluorocarbonsHydrocarbons, FluorinatedIndicators and Reagents

Identifiers

PMID17967299
PMCPMC2737259
OpenAlexW2088010486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.